170 related articles for article (PubMed ID: 23460348)
1. Effects of a human compact anti-ErbB2 antibody on gastric cancer.
Fedele C; Carvalho S; Riccio G; Paciello R; Laccetti P; Schmitt F; De Lorenzo C
Gastric Cancer; 2014 Jan; 17(1):107-15. PubMed ID: 23460348
[TBL] [Abstract][Full Text] [Related]
2. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
3. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
[TBL] [Abstract][Full Text] [Related]
4. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
[TBL] [Abstract][Full Text] [Related]
5. Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.
Shiravi F; Mohammadi M; Golsaz-Shirazi F; Bahadori T; Judaki MA; Fatemi F; Zare HA; Haghighat FN; Mobini M; Jeddi-Tehrani M; Amiri MM; Shokri F
Invest New Drugs; 2021 Jun; 39(3):697-704. PubMed ID: 33389387
[TBL] [Abstract][Full Text] [Related]
6. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
[TBL] [Abstract][Full Text] [Related]
7. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
[TBL] [Abstract][Full Text] [Related]
8. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
10. Biological properties of a human compact anti-ErbB2 antibody.
De Lorenzo C; Cozzolino R; Carpentieri A; Pucci P; Laccetti P; D'Alessio G
Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
De Lorenzo C; Troise F; Cafaro V; D'Alessio G
Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
[TBL] [Abstract][Full Text] [Related]
12. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
16. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
18. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
